|Statement||David M. Gershenson, guest editor.|
|Series||Obstetrics and gynecology clinics of North America -- v.21/1|
|Contributions||Gershenson, David M.|
|The Physical Object|
|Pagination||xii, 217p. :|
|Number of Pages||217|
Update on epithelial ovarian cancer. [David M Gershenson;] Home. WorldCat Home About WorldCat Help. Search. Search for Library Items Search for Lists Search for Contacts Search for a Library. Create Book\/a>, schema:CreativeWork\/a> ; \u00A0\u00A0\u00A0\n library. Ovarian epithelial cancer is a heterogeneous group of neoplastic diseases that can be broadly classified as type I and type II tumors. While type II ovarian cancer is composed of mostly high-grade. Despite its relatively low incidence, ovarian cancer is the seventh most frequent cause of cancer-related deaths in women, causing more than , deaths worldwide annually. Based on the presumed cells of origin, ovarian cancer is commonly classified as epithelial ovarian carcinoma (EOC), ovarian germ cell tumour or sex cord-stromal : Xiao-Ying Zhang, Pei-Ying Zhang. Books Quick Reference Johns Hopkins Handbook; Drugs MLA Citation "Epithelial Ovarian Cancer." Williams Gynecology Study Guide, 3e Werner CL, Richardson DL, Chang SY, Griffith WF, Hamid CA, Rahn DD, Moschos E, Hoffman BL.
Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book ;– doi: /EDBK_ Search PubMed; van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease process. An integrated approach with gynecologic oncologists as well as medical oncologists, pathologists, and radiologists is . BC Cancer scientists win 4 of 7 Canadian Cancer Society Research Impact grants BC Cancer’s Dr. David Huntsman named Aubrey J. Tingle Prize recipient Moving on up – new exercise resources for cancer . For many patients, the diagnosis of ovarian cancer often comes too late; its symptoms have gone ignored or undetected for too long. Now is the time to make everyone aware of risks, research, and hope for the future: September is Ovarian Cancer Awareness significant advances have been made in standard treatments for ovarian cancer, the survival rates have only modestly .
In the United States, ovarian cancer accounts for more deaths than any other gynecologic malignancy. Worldwide each year, more than , women are diagnosed, and , women die from this disease ().Of these, epithelial ovarian carcinomas make up 90 percent of all cases, including the more indolent low-malignant-potential (borderline) tumors (Torre, ). Yanwei Luo, Rong Gui, Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells, Journal of Gynecologic Oncology, /jgoe75, 31, . Epithelial ovarian cancer (EOC) is usually diagnosed late at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is pretty high. The efficacy of different targeted therapies reduces with each recurrence. Hence there is need of effective maintenance therapy in recurrent EOC. Recently, polyADP-ribose polymerase (PARP) inhibitors (PARPi) have been approved . 1. Am Soc Clin Oncol Educ Book. ; doi: /EDBK_ Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.